Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

Presentation TCT 2017

Should Recommendations for Left Main PCI Be Revised? Personal Perspectives and the Guidelines Process

Presenter: Antonio Colombo, David E. Kandzari, Stephan Windecker

October 31, 2017

Presentation TCT 2017

Controversial Position Statement: Polymer-Free DES Provide the Optimal Balance of Safety and Efficacy (and Will Improve Most in the Future)!

Presenter: Giulio G. Stefanini, Stephan Windecker, Philip M. Urban

October 30, 2017

Presentation TCT 2017

Metallic DES Are Different! How I Choose Stent Type to Match the Lesion and Patient (From 30 Years of Experience)

Presenter: Giulio G. Stefanini, Stephan Windecker, Antonio Colombo

October 30, 2017

Presentation TCT 2017

Are All Contemporary DES Comparable? Lessons From the SCAAR Registry

Presenter: Giulio G. Stefanini, Stephan Windecker, Stefan K. James

October 30, 2017

Presentation TCT 2017

Are All Contemporary DES Comparable? Lessons From the COMPARE Trials

Presenter: Giulio G. Stefanini, Stephan Windecker, Elvin Kedhi

October 30, 2017

Presentation TCT 2017

Are All Contemporary DES Comparable? Lessons From the TWENTE Trials

Presenter: Giulio G. Stefanini, Stephan Windecker, Clemens von Birgelen

October 30, 2017

Presentation TCT 2017

Are All Contemporary DES Comparable? Lessons From the SORT-OUT Trials

Presenter: Giulio G. Stefanini, Stephan Windecker, Evald H. Christiansen

October 30, 2017

Presentation TCT 2017

Are There Meaningful Differences Between Current Durable Polymer-Based vs Bioabsorbable Polymer-Based vs Polymer-Free Metallic DES? Pathologic Insights

Presenter: Giulio G. Stefanini, Stephan Windecker, Renu Virmani

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Presenter: C. Michael Gibson, Stephan Windecker

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the ABSORB III/IV Ten-Year Results Change How We Currently View Bioresorbable Vascular Scaffolds?

Presenter: C. Michael Gibson, Stephan Windecker, Stephan Achenbach

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Presenter: C. Michael Gibson, Stephan Windecker, Eric R. Bates

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing COMPLETE Trial Change the Current Recommended Approach to Multivessel Disease in STEMI?

Presenter: C. Michael Gibson, Stephan Windecker, David Hildick-Smith

October 30, 2017

Presentation TCT 2017

Emerging Secondary MR Transcatheter Repair and Replacement Therapies

Presenter: Jeroen J. Bax, Stephan Windecker, Francesco Maisano

October 29, 2017

Presentation TCT 2017

Transcatheter Mitral Valve Repair vs Medical Treatment for Severe Secondary MR

Presenter: Jeroen J. Bax, Stephan Windecker, Alec S. Vahanian

October 29, 2017

Presentation TCT 2017

Surgical Repair vs Replacement for Severe Secondary MR

Presenter: Jeroen J. Bax, Stephan Windecker, Michael A. Borger

October 29, 2017

Presentation TCT 2017

Timing of Intervention for Secondary MR: Not Too Early and Not Too Late?

Presenter: Jeroen J. Bax, Stephan Windecker, Alec S. Vahanian

October 29, 2017

Presentation TCT 2017

Biorestorative Valve: Tomorrow's World From Preclinical to Clinical

Presenter: Jeroen J. Bax, Michael A. Borger, Stephan Windecker, Patrick W. Serruys

October 29, 2017

Presentation TCT 2017

DAPT Duration: Individualized vs Generalized Approach

Presenter: Jeroen J. Bax, Michael A. Borger, Stephan Windecker, Marco Valgimigli

October 29, 2017

Presentation TCT 2017

Debate: STEMI With Multivessel Disease - Staged (Culprit) Lesion Revascularization Followed by Noninvasive Risk Stratification Is Currently Indicated

Presenter: Jeroen J. Bax, Michael A. Borger, Stephan Windecker, Giulio G. Stefanini

October 29, 2017

Presentation TCT 2017

Debate: STEMI With Multivessel Disease - Immediate (or Early) Routine Complete Revascularization Is the Way to Go

Presenter: Jeroen J. Bax, Michael A. Borger, Stephan Windecker, Anthony H. Gershlick

October 29, 2017

Advertisement

Should Recommendations for Left Main PCI Be Revised? Personal Perspectives and the Guidelines Process

Controversial Position Statement: Polymer-Free DES Provide the Optimal Balance of Safety and Efficacy (and Will Improve Most in the Future)!

Metallic DES Are Different! How I Choose Stent Type to Match the Lesion and Patient (From 30 Years of Experience)

Are All Contemporary DES Comparable? Lessons From the SCAAR Registry

Are All Contemporary DES Comparable? Lessons From the COMPARE Trials

Are All Contemporary DES Comparable? Lessons From the TWENTE Trials

Are All Contemporary DES Comparable? Lessons From the SORT-OUT Trials

Are There Meaningful Differences Between Current Durable Polymer-Based vs Bioabsorbable Polymer-Based vs Polymer-Free Metallic DES? Pathologic Insights

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Predicting The Future: Will the ABSORB III/IV Ten-Year Results Change How We Currently View Bioresorbable Vascular Scaffolds?

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Predicting the Future: Will the Ongoing COMPLETE Trial Change the Current Recommended Approach to Multivessel Disease in STEMI?

Emerging Secondary MR Transcatheter Repair and Replacement Therapies

Transcatheter Mitral Valve Repair vs Medical Treatment for Severe Secondary MR

Surgical Repair vs Replacement for Severe Secondary MR

Timing of Intervention for Secondary MR: Not Too Early and Not Too Late?

Biorestorative Valve: Tomorrow's World From Preclinical to Clinical

DAPT Duration: Individualized vs Generalized Approach

Debate: STEMI With Multivessel Disease - Staged (Culprit) Lesion Revascularization Followed by Noninvasive Risk Stratification Is Currently Indicated

Debate: STEMI With Multivessel Disease - Immediate (or Early) Routine Complete Revascularization Is the Way to Go

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content